Hsbc Holdings PLC Has $764,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Hsbc Holdings PLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 64.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,337 shares of the biopharmaceutical company's stock after purchasing an additional 14,269 shares during the quarter. Hsbc Holdings PLC's holdings in Catalyst Pharmaceuticals were worth $764,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of CPRX. State of Tennessee Department of Treasury grew its stake in shares of Catalyst Pharmaceuticals by 4.5% in the 4th quarter. State of Tennessee Department of Treasury now owns 50,587 shares of the biopharmaceutical company's stock valued at $1,056,000 after buying an additional 2,193 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Catalyst Pharmaceuticals by 242.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,491 shares of the biopharmaceutical company's stock worth $553,000 after purchasing an additional 18,759 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Catalyst Pharmaceuticals by 6.9% during the 4th quarter. MetLife Investment Management LLC now owns 68,087 shares of the biopharmaceutical company's stock valued at $1,421,000 after purchasing an additional 4,413 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $2,437,000. Finally, Canada Pension Plan Investment Board bought a new stake in Catalyst Pharmaceuticals in the fourth quarter worth $1,244,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.40% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Stock Up 2.7 %

NASDAQ CPRX traded up $0.61 during midday trading on Friday, hitting $23.37. The company had a trading volume of 1,551,587 shares, compared to its average volume of 1,111,360. The firm has a fifty day simple moving average of $22.99 and a two-hundred day simple moving average of $22.39. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 19.81, a P/E/G ratio of 3.31 and a beta of 0.70.

Analysts Set New Price Targets

CPRX has been the subject of several recent analyst reports. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Stephens restated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.